• 12 Dec 2013

    New Payer Challenges in a Shifting Hepatitis C Landscape

    Matthew LaForgia, , Zitter Health Insights

    In a November 4th article, the New York Times heralded the arrival of a new generation of Hepatitis C drugs as “an enormous public health achievement.” Indeed, over the next few years several drugs are expected to come to market that significantly aim to improve patient outcomes. But how will payers respond to new entrants in what […]

    read more
  • 26 Nov 2013

    Another Way to Look at Premium Cost Variability in the Health Insurance Marketplace

    Anita Murell, Analyst, New Product Development, Zitter Health Insights

    What does it mean when an insurer says it offers plans “in” a state? Does that mean everyone in the state can buy that plan? Unfortunately not. Insurers may elect to offer their plans in a certain geographic region, and some regions are more favorable demographically than others to insurers. Let’s take the case of […]

    read more
  • 12 Nov 2013

    Zitter Health Insights Launches Hep C Impact Monitor

    ZHI, Zitter Health Insights

    HEP C: STAKEHOLDERS PREPARE FOR INTERFERON-FREE REGIMENS AND USPSTF RECOMMENDATION ON SCREENING Understanding how stakeholders intend to respond may lead to delivery of better care. November 12, 2013, San Francisco, CA – The approval of interferon-free regimens to treat Hepatitis C is expected to change the care paradigm for millions of U.S. patients. Patients who […]

    read more
  • 07 Nov 2013

    Reflections from a Health Exchange Researcher: Part 2

    Boris Gorsh, Manager, Prior Authorization Tracking Tool, Zitter Health Insights

    Now that a full month has passed since the opening of the Health Exchange Marketplace, there has been some more clarity into the variety of plans available. What is still somewhat unclear, is the impact that all these plan types may have on patient access to specialty medications. For example: Ambetter offers a gold plan […]

    read more
  • 04 Nov 2013

    Drug Prices vs. Pharmaceutical Spending

    Mark Zitter, CEO, Zitter Health Insights

    Drug pricing and drug expenditures are frequently criticized for being too high. But many Americans don’t distinguish between the two. They are quite different, and the difference matters. There’s no question that most branded drugs tend to have high prices, especially those developed via biologic processes and indicated for relatively small groups of patients. There […]

    read more